Dominic Clark

AI Summary

→ WHAT IT COVERS Dominic Clark, VP of Technical Operations at IntegraCell (Cryoport Systems), explains why cell therapy programs default to fresh leukapheresis workflows, how late-stage cryopreservation adoption creates costly regulatory and operational problems, and how IntegraCell's automated closed process standardizes starting material handling from early development through global commercialization. → KEY INSIGHTS - **Fresh vs. Frozen Starting Material:** Fresh workflows persist due to inherited academic processes, not data superiority. Once programs enter the clinic with fresh workflows, those decisions become locked in — making later pivots costly and regulatory-intensive. Teams should evaluate cryopreservation at Phase I design, not during scale-up, to avoid forced process changes under high regulatory scrutiny. - **Automated Closed Process (ACP) Design:** IntegraCell's ACP uses a Fresenius Kabi Q system to automate leukapheresis washing, concentration, cryoprotectant formulation, and bag filling in a closed system. This removes operator-dependent manual handling steps, reducing two primary variability sources — time and people — while producing cell viability and recovery comparable to fresh starting material. - **Cryopreservation as Regulatory Strategy:** Validated cryopreservation strengthens regulatory submissions by demonstrating reproducibility and process control. Data from an IntegraCell-CellAd collaboration showed the ACP preserves key T cell subsets, activation profiles, and phenotypic identity at levels functionally equivalent to fresh material, providing documented evidence regulators can assess for consistency across manufacturing batches. - **Multi-Site Standardization Gap:** A single validated cryopreservation process deployed across multiple collection sites eliminates site-to-site variation. IntegraCell addresses this by offering the same ACP protocol, quality system, and SOPs across all global locations — including a Paris facility opened in 2024 and a Southern California site opening in 2025 — rather than allowing each site to run independent manual variants. - **Proactive Dual-Track Planning:** Programs committed to fresh workflows should still develop and validate a cryopreserved starting material option in parallel. Maintaining a frozen backup decouples manufacturing from clinical scheduling, enables inventory management, and provides operational flexibility if logistics, patient geography, or scale demands shift — without requiring a disruptive mid-program process change under regulatory review. → NOTABLE MOMENT Clark reframes the core tradeoff by arguing that fresh workflows optimize for immediacy while frozen workflows optimize for scale — and that the real source of quality risk in cell therapy is not freezing itself, but uncontrolled variability introduced through manual handling and fragmented multi-vendor handoffs. 💼 SPONSORS None detected 🏷️ Cell Therapy Manufacturing, Cryopreservation, Leukapheresis Processing, Supply Chain Standardization, Biotech Scale-Up